Sentences with phrase «biomarker development»
"Biomarker development" refers to the identification and creation of a measurable characteristic or substance in the body that can indicate the presence, progression, or risk of a disease or condition. These biomarkers are used to diagnose, monitor, and determine the effectiveness of treatments. Full definition
Our study has several important findings that have implications for biomarker development for this class of drugs.
jcancer.org
To this end his lab currently oversees three NIH - funded clinical trials that focus on biomarker development in cerebrovascular and lymphatic diseases.
Dr. Anna D. Barker, Co-director, Complex Adaptive Systems (CAS); Director, National Biomarker Development Alliance; Professor, School of Life Sciences, Arizona State University Dr. Luis Diaz, Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center.
«We currently lack a coordinated approach in biomarker development at European and international level,» Prof Giovanni Frisoni from the University of Geneva in Switzerland told the Congress.
More importantly, they also identified a few proteins that previously were not known to be HCC - related, opening possibilities for candidate biomarker development.
International experts have now drawn up a five - phase framework for biomarker development, which was unveiled at the Second Congress of the Europe Academy of Neurology (EAN) in Copenhagen.
Research Interests: Asthma, Pulmonary Hypertension, Biomarker development, Biorepository, Primary cell culture
[30, 32, 33] This significant degree of genetic heterogeneity may present a major challenge to biomarker development.
You will also be expected to participate in the design and execution of pharmacology studies to support MOA characterization, biomarker development, and clinical dose prediction.
Biomarker Discovery: The Translational Neuroscience Center at Boston Children's Hospital has access to world - class facilities for biomarker development and state - of - the - art brain imaging.
The goal is to define selective vulnerabilities that can guide novel therapeutic approaches and biomarker development.
Through this partnership and membership in the ETCTN, the three institutions will combine their expertise in clinical care, basic science research, molecular genomic and proteomic profiling and biomarker development.